Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension studyMichael R. McClung, Henry G. Bone, Bente Langdahl et al.|The Lancet Diabetes & Endocrinology|2019Cited by 171
Safety and Tolerability of Odanacatib Therapy in Postmenopausal Women with Osteoporosis: Results from the Phase III Long-Term Odanacatib Fracture Trial (LOFT)Socrates E. Papapoulos, Deborah M. Gurner, Michael R. McClung et al.|Data Archiving and Networked Services (DANS)|2014Cited by 3